Kineta, Inc./De financial data

Symbol
KANT on OTC
Industry
Pharmaceutical Preparations
Location
7683 Se 27 Th Street, Suite 481, Mercer Island, WA
State of incorporation
DE
Fiscal year end
December 31
Former names
YUMANITY THERAPEUTICS, INC. (to 12/16/2022), PROTEOSTASIS THERAPEUTICS, INC. (to 12/16/2020), PROTEOSTASIS THERAPEUTICS INC (to 6/2/2011)
Latest financial report
10-K - Q4 2024 - Mar 6, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 15.8 % -84.4%
Debt-to-equity -118 % -140%
Return On Equity 192 %
Return On Assets -969 % -786%
Operating Margin -303 % +87.3%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 12.3M shares +11.9%
Common Stock, Shares, Outstanding 12.3M shares +18%
Entity Public Float 2.5M USD -75.7%
Common Stock, Value, Issued 12K USD +20%
Weighted Average Number of Shares Outstanding, Basic 12.1M shares +9.46%
Weighted Average Number of Shares Outstanding, Diluted 12.1M shares +9.46%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 0 USD -100%
Revenue from Contract with Customer, Excluding Assessed Tax 0 USD
Research and Development Expense 5.39M USD -40.3%
General and Administrative Expense 8.15M USD -32.9%
Operating Income (Loss) -13.5M USD +13.9%
Nonoperating Income (Expense) -3.61M USD -319%
Net Income (Loss) Attributable to Parent -17.1M USD -21.5%
Earnings Per Share, Basic -1.42 USD/shares -10.9%
Earnings Per Share, Diluted -1.42 USD/shares -10.9%

Balance Sheet

Label TTM Value / Value Unit Change %
Assets, Current 1.02M USD -83%
Property, Plant and Equipment, Net 0 USD
Operating Lease, Right-of-Use Asset 0 USD -100%
Assets 1.02M USD -90.1%
Accounts Payable, Current 3.9M USD +5.6%
Employee-related Liabilities, Current 696K USD -47%
Accrued Liabilities, Current 2.36M USD +6.78%
Liabilities, Current 12.9M USD +82.2%
Operating Lease, Liability, Noncurrent 0 USD -100%
Liabilities 12.9M USD +78.4%
Retained Earnings (Accumulated Deficit) -183M USD -10.3%
Stockholders' Equity Attributable to Parent -12M USD -516%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest -11.9M USD -488%
Liabilities and Equity 1.02M USD -90.1%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -4.01M USD +18.8%
Net Cash Provided by (Used in) Financing Activities 750K USD
Net Cash Provided by (Used in) Investing Activities 0 USD -100%
Common Stock, Shares Authorized 125M shares 0%
Common Stock, Shares, Issued 12.3M shares +18%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -4.01M USD -2.69%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 638K USD -89.1%
Interest Paid, Excluding Capitalized Interest, Operating Activities 5K USD -61.5%
Deferred Tax Assets, Valuation Allowance 178M USD +1.66%
Deferred Tax Assets, Gross 178M USD +1.62%
Operating Lease, Liability 81K USD -91.7%
Payments to Acquire Property, Plant, and Equipment 0 USD -100%
Lessee, Operating Lease, Liability, to be Paid 796K USD
Property, Plant and Equipment, Gross 0 USD -100%
Operating Lease, Liability, Current 0 USD -100%
Lessee, Operating Lease, Liability, to be Paid, Year Two 561K USD
Lessee, Operating Lease, Liability, to be Paid, Year One 81K USD -82.8%
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 0 USD -100%
Deferred Tax Assets, Operating Loss Carryforwards 148M USD +1.98%
Unrecognized Tax Benefits 1.08M USD +7.7%
Operating Lease, Payments 157K USD -77.6%
Additional Paid in Capital 171M USD +1.31%
Depreciation, Depletion and Amortization 0 USD -100%
Deferred Tax Assets, Net of Valuation Allowance 49K USD -57.4%
Share-based Payment Arrangement, Expense 1.24M USD -67.8%
Interest Expense 367K USD -86.1%